Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,25
PKN96,4696,62,33
Msft-1,16
Nokia4,7464,792,40
IBM-0,76
Daimler AG47,4247,435-0,17
PFE0,49
21.09.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.09.2019 21:59:30
PDL BioPharma (PDLI.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
2,16 0,47 0,01 2 136 558
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.09.2019
Popis společnosti
Obecné informace
Název společnostiPDL BioPharma Inc
TickerPDLI
Kmenové akcie:Ordinary Shares
RICPDLI.O
ISINUS69329Y1047
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 30.06.2019 107
Akcie v oběhu k 30.07.2019 114 202 671
Počet akcionářů k 31.12.2018 127
MěnaUSD
Kontaktní informace
Ulice932 Southwood Blvd
MěstoINCLINE VILLAGE
PSČ89451
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 758 328 500
Fax17758328501

Business Summary: PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
Financial Summary: BRIEF: For the six months ended 30 June 2019, PDL BioPharma Inc revenues decreased 81% to $16.4M. Net income totaled $2.3M vs. loss of $110.7M. Revenues reflect Pharmaceutical segment decrease of 31% to $30.4M. Net Income reflects Impairment of intangible assets decrease from $152.3M (expense) to $0K, Amortization of intangible assets decrease of 75% to $3.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 22.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorDominique Monnet6031.12.201811.09.2017
Chief Accounting Officer, Vice President - FinanceEd Imbrogno5520.06.201920.06.2019
Vice President, General Counsel, SecretaryChristopher Stone5402.02.200902.02.2009
Vice President, Business DevelopmentJill Jene46